Chinese PLA General Hospital
Beijing, Beijing Municipality, 100089, China
Location status: Recruiting
NCT Number: NCT07115277
The goal of this clinical trial is to evaluate the diagnostic performance and safety of Flotufolastat F-18 injection PET imaging in prostate cancer subjects with biochemical recurrence following prior treatment. The main question it aims to answer is:
• What is the correct detection rate of Flotufolastat F 18 injection PET visual reading results compared to the truth standard?
Participants will:
* Receive Flotufolastat F-18 injection * Undergo PET/CT scanning
Interested in participating?
Request Info18 year and older
Male
Interventional
Not applicable
Beijing, Beijing Municipality, 100089, China
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
All patients will receive one injection of Flotufolastat F-18 Injection, a PET radiopharmaceutical selective for PSMA. For the injection, subjects will receive a target dose of 8 mCi (296 MBq) ± 20% IV as a bolus injection. Flotufolastat F-18 Injection will be followed by a 10 ml saline flush.
Time frame: 90 days
Correct Detection Rate (CDR) at the individual level of Flotufolastat F-18 Injection PET imaging in prostate cancer subjects with BCR
Time frame: 90 days
Positive predictive value (PPV) of Flotufolastat F-18 Injection PET imaging at the individual level in prostate cancer subjects with BCR.
PPV and CDR of Flotufolastat F-18 Injection PET imaging in the prostate bed, pelvic lymph nodes, and three other regions in Chinese prostate cancer subjects with BCR.
Time frame: 90 days
Individual-level PPV and CDR of Flotufolastat F-18 Injection PET imaging in subjects whose baseline conventional imaging is negative.
Individual-level PPV and CDR of Flotufolastat F-18 Injection PET imaging at different PSA levels.
Time frame: 90 days
Kappa values for inter-reader and intra-reader agreement in the interpretation of the same Flotufolastat F-18 Injection PET imaging by different independent blinded readers and by the same reader at different times.
Time frame: 3 days
The types, severity, frequency, and outcomes of adverse events/serious adverse events reported during the study period.
Contact information is provided by the study sponsor or research team.
Sinotau Pharmaceutical Group
Industry
A Single-arm, Multicenter, Phase III Clinical Trial , Evaluate the Diagnostic Performance and Safety of Flotufolastat F-18 Injection PET Imaging in Prostate Cancer Subjects With Biochemical Recurrence Following Prior Treatment
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06625970
Genital Diseases, Genital Diseases, Male
Brest, France
View Trial DetailsNCT06954337
Breast Cancer, Breast Diseases
Basking Ridge, New Jersey, United States
View Trial DetailsNCT02960022
Genital Diseases, Genital Diseases, Male
Anchorage, Alaska, United States
View Trial DetailsNCT07005154
Genital Diseases, Genital Diseases, Male
Huntsville, Alabama, United States
View Trial Details